therapy-resistent reduction of range of motion in infants with perthes disease
Conditions
Interventions
Trade Name: Dysport
Pharmaceutical Form: Powder for injection*
Sponsors
AKH Wien, Universitätsklinik für Physikalische Medizin und Rehabilitation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: * infants with perthes disease * age 5 to 12 years * reduction of abduction of the hip to = 40° and/or difference of = 20° to the opposite side persisting after minimal 2 month of intensive physiotherapy Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: * neuromuscular diseases * serious dysphagia * medication with antibiotics * anticoagulation, coagulopathy * clinical or laboratory signs of local of generalised infection * lack of cooperation * participation on other clinical trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Secondary Objective: Secondary objectives are reduction of pain and improvement of life quality;Primary end point(s): changes in range of motion, pain level, quality of life weekly evaluation until 8 months after botulinum toxin treatment;Main Objective: the main objective is an improvement of range of motion by a combination of botulinum toxin and physiotherapy in perthes disease | — |
Countries
Austria
Outcome results
None listed